Orchard Therapeutics Further Strengthens Board of Directors with Appointment of John Curnutte, M.D., Ph.D.
August 30, 2019 08:00 ET | Orchard Therapeutics
BOSTON and LONDON, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with...
Orchard Therapeutics Announces Presentation of Data from Neurometabolic Portfolio at Upcoming Society for the Study of Inborn Errors of Metabolism (SSIEM) 2019 Annual Symposium
August 27, 2019 07:00 ET | Orchard Therapeutics
BOSTON and LONDON, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with...
Orchard Therapeutics Reports Second Quarter 2019 Financial Results and Builds Momentum Ahead of Regulatory Filings
August 08, 2019 07:00 ET | Orchard Therapeutics
Metachromatic Leukodystrophy (MLD) MAA Submission and Initiation of ADA-SCID Rolling BLA Expected in the First Half of 2020; OTL-103 Recently Granted RMAT Designation for Wiskott-Aldrich Syndrome...
Orchard Therapeutics to Webcast Presentation at the 2019 Wedbush PacGrow Healthcare Conference
August 06, 2019 07:00 ET | Orchard Therapeutics
BOSTON and LONDON, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with...
Orchard Therapeutics to Webcast Conference Call of Second Quarter 2019 Financial Results
August 01, 2019 07:00 ET | Orchard Therapeutics
BOSTON and LONDON, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with...
Orchard Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted for OTL-103 for the Treatment of Wiskott-Aldrich Syndrome
July 29, 2019 07:00 ET | Orchard Therapeutics
Three-Year Registrational Data Set to be Presented by Year End 2019 Regulatory Submissions Planned in the U.S. and Europe for 2021 BOSTON and LONDON, July 29, 2019 (GLOBE NEWSWIRE) -- Orchard...
Orchard Therapeutics to Present at the Goldman Sachs 40th Annual Global Healthcare Conference on June 12, 2019
June 10, 2019 07:00 ET | Orchard Therapeutics
BOSTON and LONDON, June 10, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with...
Orchard Therapeutics Announced Pricing of Public Offering
June 05, 2019 19:59 ET | Orchard Therapeutics
BOSTON and LONDON, June 05, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with...
Orchard Therapeutics Launches Proposed Public Offering
June 03, 2019 16:05 ET | Orchard Therapeutics
BOSTON and LONDON, June 03, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with...
Orchard Therapeutics Announces Expansion of Neurometabolic Disease Portfolio and Reports First Quarter 2019 Financial Results
May 28, 2019 07:15 ET | Orchard Therapeutics
New Collaboration with Fondazione Telethon and Ospedale San Raffaele for Clinical Program in Mucopolysaccharidosis Type I (MPS-I) Using Ex Vivo Autologous Hematopoietic Stem Cell Gene Therapy ...